Management
Erez AminovChairman and CEO Strategic architect of pipeline and capital markets activity.
Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing Telomir-Zn, a novel oral epigenetic therapy for patients with advanced triple-negative breast cancer (TNBC). Under his leadership, the company advanced Telomir-Zn through preclinical development to FDA IND clearance for a Phase 1/2 clinical trial.
Mr. Aminov leads Telomir’s corporate strategy, financing, business development, intellectual property, and clinical execution. He has successfully structured and executed multiple strategic transactions, including worldwide licensing agreements, acquisitions of global development and commercialization rights, and business development initiatives that have strengthened the Company’s intellectual property portfolio.
Mr. Aminov also serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), where he has overseen the advancement of one clinical-stage development program together with additional preclinical pipeline assets and successfully led the company through its initial public offering.
Before leading public biotechnology companies, Mr. Aminov worked as a consultant, advising on corporate strategy, business development, and strategic transactions within the biotechnology sector.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University.
Mr. Aminov leads Telomir’s corporate strategy, financing, business development, intellectual property, and clinical execution. He has successfully structured and executed multiple strategic transactions, including worldwide licensing agreements, acquisitions of global development and commercialization rights, and business development initiatives that have strengthened the Company’s intellectual property portfolio.
Mr. Aminov also serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), where he has overseen the advancement of one clinical-stage development program together with additional preclinical pipeline assets and successfully led the company through its initial public offering.
Before leading public biotechnology companies, Mr. Aminov worked as a consultant, advising on corporate strategy, business development, and strategic transactions within the biotechnology sector.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University.
Itzchak Angel, PhDChief Scientific Advisor40+ years of drug discovery experience. Former Head of Pharmacology, Sanofi/Synthalabo. Pipeline architect.
Itzchak Angel is an accomplished executive in the pharmaceutical industry, with over 40 years’ experience guiding medical, pharmaceutical, drug and business development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.) where he assists pharmaceutical and biotechnology companies, individuals, medical staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development. In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors, and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business development, and organizational planning.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel’s previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel’s previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Andriy Mushak, CPAChief Financial Officer20+ years of SEC reporting, public company finance, compliance, and capital markets experience.
Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing.
Prior to co-founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.
Prior to co-founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.
Alex Weisman, Ph.D.Scientific Advisor30+ years leading CMC, regulatory strategy, and clinical development across multiple therapeutic areas.
Dr. Alex Weisman, Ph.D. in biochemistry, is the founder and owner of Calathea Pharma Ltd., a consulting company providing scientific and business development services in Chemistry, Manufacturing, and Controls for companies and government institutions. Dr. Weisman has held executive positions as VP R&D and Chief Scientist at a number of Israeli and international pharmaceutical companies and currently serves as an advisor and management team member of companies developing new products for the chemicals, pharmaceuticals, and food industries. With more than 30 years of experience in the development, characterization, scale-up, technology transfer, troubleshooting, production, and registration of novel and generic drugs, as well as other pharmaceutical and chemical products, Dr. Weisman brings extensive expertise to his consulting role.